STOCK TITAN

AIkido Pharma Inc - aiki STOCK NEWS

Welcome to our dedicated news page for AIkido Pharma (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on AIkido Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIkido Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIkido Pharma's position in the market.

Rhea-AI Summary
DatChat, Inc. (Nasdaq: DATS) announces 1-for-10 reverse stock split to meet Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
DATCHAT announces a 1:10 reverse stock split to comply with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
DatChat to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
conferences
Rhea-AI Summary
DatChat files patent application for Secure Group Based Asset Access and surpasses 100,000 members in its metaverse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.41%
Tags
none
-
Rhea-AI Summary
DatChat partners with Cloud Water Brands to promote their products within the Habytat Virtual World.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
partnership
-
Rhea-AI Summary
DatChat reaches milestone of over 75,000 active users in Habytat metaverse, with accelerated adoption of AI-powered HabyPets. Company confident in converting user growth into revenue streams. Expectation of higher user growth with new product releases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
AI
Rhea-AI Summary
DatChat launches AI-powered pets called HabyPets in its Habytat metaverse, with initial breeds including Shiba Inu, German Shepherd, Golden Retriever, and Schnauzer. Pets require daily care and training. Revenue growth expected from advertisements and product placements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
Rhea-AI Summary
DATS: DatChat Receives USPTO Allowance for Secure Web RTC Real Time Communication Service Patent. The patent enhances security for audio and video streaming communications, further solidifying DatChat's commitment to protecting user information and expanding capabilities in the metaverse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
conferences
AIkido Pharma Inc

Nasdaq:AIKI

AIKI Rankings

AIKI Stock Data

19.53M
Payroll Services
Professional, Scientific, and Technical Services
Link
US
New York

About AIKI

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.